| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.273.46.30517 |
| P698 | PubMed publication ID | 9804820 |
| P50 | author | Aysegul Nalca | Q62478502 |
| P2093 | author name string | V M Rangnekar | |
| P2860 | cites work | The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 |
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| Induction of the growth inhibitor IGF-binding protein 3 by p53 | Q28289896 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Tumor suppressor p53 is a direct transcriptional activator of the human bax gene | Q28306186 | ||
| Apoptosis, cancer and the p53 tumour suppressor gene | Q28611432 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA | Q29615251 | ||
| Cancer. p53, guardian of the genome | Q29615610 | ||
| Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Interleukin 1: the first interleukin. | Q34372820 | ||
| p53: oncogene or anti-oncogene? | Q34627381 | ||
| Two TNF receptors | Q35231014 | ||
| p53 function and dysfunction | Q35721291 | ||
| Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function | Q36562198 | ||
| The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest | Q36566521 | ||
| Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. | Q36665942 | ||
| Wild-type p53 is a cell cycle checkpoint determinant following irradiation | Q37152060 | ||
| Wild-type p53 can down-modulate the activity of various promoters | Q37617210 | ||
| There is more than one interleukin 1. | Q38257771 | ||
| Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter | Q38288588 | ||
| EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells | Q38351455 | ||
| An update on human interleukin-1: from molecular biology to clinical relevance | Q39832526 | ||
| A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis | Q40019792 | ||
| Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. | Q40020159 | ||
| p53 and human cancers. | Q40648173 | ||
| The tumor suppressor genes | Q40856821 | ||
| Cytostatic effect of TNFalpha on cancer cells is independent of p21WAF1. | Q41085041 | ||
| Early growth response-1-dependent apoptosis is mediated by p53. | Q41094563 | ||
| Interleukin-1 induces growth arrest by hypophosphorylation of the retinoblastoma susceptibility gene product RB. | Q41217469 | ||
| Growth factor modulation of p53-mediated growth arrest versus apoptosis | Q41365779 | ||
| p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes | Q41454039 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| Induction of apoptosis in HeLa cells by trans-activation-deficient p53 | Q53461564 | ||
| Life (and death) in a malignant tumour | Q59098941 | ||
| Recessive oncogenes | Q70548938 | ||
| Oncogenes and cell proliferation | Q71497095 | ||
| Evidence for a p53‐independent pathway for upregulation of SDI1/CIP1/WAF1/P21 RNA in human cells | Q71647788 | ||
| P433 | issue | 46 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 30517-30523 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | The G1-phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function | |
| P478 | volume | 273 |
| Q37288401 | A role for interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells |
| Q43970143 | Accumulation of an inactive form of p53 protein in cells treated with TNF alpha |
| Q31633427 | Altered regulation of cell cycle machinery involved in interleukin-1-induced G(1) and G(2) phase growth arrest of A375S2 human melanoma cells |
| Q38401970 | Interleukin-1 modulation of human placental trophoblast proliferation |
| Q34937637 | Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. |
| Q33967914 | Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. |
| Q55481390 | Monocyte Response to Different Campylobacter jejuni Lysates Involves Endoplasmic Reticulum Stress and the Lysosomal⁻Mitochondrial Axis: When Cell Death Is Better Than Cell Survival. |
| Q83204740 | The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients |
| Q35221333 | Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases |
Search more.